Impact of salvage chemotherapy after immune checkpoint inhibitor for recurrent or metastatic head and neck cancer

被引：0
|
作者：
Matoba, Takuma [1 ]
Minohara, Kiyoshi [1 ]
Kawakita, Daisuke [1 ,7 ]
Sawabe, Michi [2 ]
Takano, Gaku [3 ]
Oguri, Keisuke [4 ]
Murashima, Akihiro [1 ]
Iwaki, Sho [1 ]
Tsuge, Hiroshi [1 ]
Imaizumi, Sae [5 ]
Hojo, Wataru [4 ]
Kondo, Ayano [1 ]
Tsukamoto, Koji [6 ]
Iwasaki, Shinichi [1 ]
机构：
[1] Nagoya City Univ, Dept Otorhinolaryngol Head & Neck Surg, Grad Sch Med Sci, Nagoya, Japan
[2] Toyota Kosei Hosp, Dept Otorhinolaryngol, Toyota, Japan
[3] Nagoya City Univ, Dept Otorhinolaryngol, West Med Ctr, Nagoya, Japan
[4] Anjo Kosei Hosp, Dept Otorhinolaryngol, Anjo, Japan
[5] Japanese Fdn Canc Res, Dept Head & Neck Surg, Canc Inst Hosp, Tokyo, Japan
[6] Aichi Canc Ctr Hosp, Dept Head & Neck Surg, Nagoya, Japan
[7] Nagoya City Univ, Dept Otorhinolaryngol Head & Neck Surg, Grad Sch Med Sci, 1 Kawasumi,Mizuho Cho,Mizuho Ku, Nagoya, Aichi 4678601, Japan
来源：
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2024年 / 46卷 / 08期
基金：
日本学术振兴会;
关键词：
head and neck cancer; immune checkpoint inhibitor; immune-related adverse effects; paclitaxel monotherapy; salvage chemotherapy; SQUAMOUS-CELL CARCINOMA; COMBINATION; CETUXIMAB; PROGRESSION; PACLITAXEL; NIVOLUMAB;
D O I：
10.1002/hed.27643
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
BackgroundIt is unclear witch regimen is optimal as salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) monotherapy for recurrent or metastatic head and neck cancer (RM-HNC).MethodsThis study enrolled 109 patients. Overall survival (OS) and progression-free survival 2 (PFS2) were compared between patients stratified by SCT regimen.ResultsOf the 109 patients, 55 underwent SCT after the failure of ICI monotherapy. The OS of these 55 patients was longer than that of patients who did not undergo SCT. The OS and PFS2 were similar between patients treated with paclitaxel (PTX) and cetuximab (Cmab) combination and those treated with PTX monotherapy. The occurrence of irAEs did not impact PFS2 nor OS.ConclusionsSCT can improve the survival outcomes of patients with RM-HNC. In addition to PTX and Cmab, PTX monotherapy is also considered an effective SCT regimen. SCT is effective regardless of the presence or absence of irAEs.
引用
收藏
页码：1855 / 1864
页数：10
相关论文
共 50 条
  • [41] Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer
    Machtay, M
    Rosenthal, DI
    Chalian, AA
    Lustig, R
    Hershock, D
    Miller, L
    Weinstein, GS
    Weber, RS
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (01): : 72 - 77
  • [42] Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis
    Jin, Zhe
    Zhang, Bin
    Zhang, Lu
    Huang, Wenhui
    Mo, Xiaokai
    Chen, Qiuyin
    Wang, Fei
    Chen, Zhuozhi
    Li, Minmin
    Zhang, Shuixing
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [43] Immune checkpoint expression in head and neck cancer
    Puntigam, L.
    Jeske, S.
    Brunner, C.
    Hoffmann, T.
    Schuler, P.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 96 - 97
  • [44] Immune Checkpoint Inhibition in Head and Neck Cancer
    Forster, Martin David
    Devlin, Michael-John
    [J]. FRONTIERS IN ONCOLOGY, 2018, 8
  • [45] Efficacy of second and subsequent lines of chemotherapy for recurrent and metastatic head and neck cancer
    Koyama, Satoshi
    Fujiwara, Kazunori
    Morisaki, Tsuyoshi
    Miyake, Naritomo
    Fukuhara, Takahiro
    Takeuchi, Hiromi
    [J]. AURIS NASUS LARYNX, 2021, 48 (01) : 161 - 165
  • [46] SAFETY PROFILE OF CHEMOTHERAPY WITH DOCETAXEL AND CISPLATIN FOR RECURRENT OR METASTATIC HEAD AND NECK CANCER
    Shimada, T.
    Kiyota, N.
    Imamura, Y.
    Nishimura, M.
    Funakoshi, Y.
    Tomioka, H.
    Toyoda, M.
    Chayahara, N.
    Mukohara, T.
    Minami, H.
    [J]. ANNALS OF ONCOLOGY, 2013, 24
  • [47] Apatinib combined with oral chemotherapy in patients with recurrent/metastatic head and neck cancer
    Dou, S.
    Li, R.
    Xie, L.
    Wang, Z.
    Zhang, C.
    Zhang, L.
    Zhu, G.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 132 : 45 - 46
  • [48] COX-2 Inhibitor and Gefitinib in Recurrent And/or Metastatic Head & Neck Cancer
    Bhattacharyya, G. S.
    Malhotra, H.
    Babu, K. Govind
    Biswas, G.
    Ranade, A. A.
    Parikh, P. M.
    Chaturvedi, P.
    Basu, S.
    Shahid, T.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S569 - S570
  • [49] Recurrent head and neck cancer - salvage therapy options
    Lukaszczyk-Widel, Beata
    Widel, Maciej
    Skladowski, Krzysztof
    [J]. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2008, 12 (04): : 187 - 191
  • [50] Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Suzuki, Shinsuke
    Toyoma, Satoshi
    Kawasaki, Yohei
    Koizumi, Koh
    Iikawa, Nobuko
    Shiina, Kazuhiro
    Endo, Tentaro
    Abe, Tomoe
    Kouga, Teppei
    Yamada, Takechiyo
    [J]. MEDICINA-LITHUANIA, 2021, 57 (11):
12345